Prevalence of serious mental illness, and treatment-resistant schizophrenia in particular, is higher in correctional settings than the general population. Management of this patient population, which is chronically nonadherent with treatment, is extremely challenging. The presenters will review the available formulations of depot neuroleptics, their associated adverse effects, and pharmacology. Standards of monitoring and management of side effects will be explored. Finally, the presenters will share successful cases where off-label dosing and frequency of depot formulations were used.

• Review available depot antipsychotic formulations and pharmacology
• Discuss necessary monitoring and recognition of adverse effects of depot antipsychotics
• Describe off-label dosing and administration for treatment-resistant patients with schizophrenia

Level: Basic